. 2018 Oct 10;7(12):1280–1287. doi: 10.1530/EC-18-0215
This work is licensed under a Table 2.
Summary of characteristics of the 28 patients at diagnosis of CD.
| All 15F/13M | op’DDD group | TSS group | op’DDD vs TSS | |
|---|---|---|---|---|
| N | 28 | 9 | 13 | |
| Age (year (s.d.)) | 12.1 (2.2) | 12.0 (1.5) | 12.0 (2.6) | NS |
| Height (z-score (s.d.)) | −1.7 (1.6) | −0.8 (1.2) | −2.2 (1.4) | NS |
| Growth velocity (z-score) (s.d.)) | −4.0 (0.9) | −3.7 (0.9) | −4.1 (0.9) | NS |
| BMI (z-score (s.d.)) | 2.6 (2.2) | 2.3 (1.4) | 21 (1.4) | NS |
| MPC (µg/dL (s.d.)) N < 3.5 | 18.9 (6.2) | 16.8 (5.7) | 17.6 (5.8) | NS |
| UFC (µg/24 h (s.d.)) N < 60 | 285 (148) | 263 (159) | 268 (140) | NS |
| ACTH (pg/mL (s.d.)) N 10–60 | 48.5 (35.7) | 68.8 (53.6) | 64.2 (52) | NS |
Mitotane group: nine patients who received more than 6 months of mitotane at initial presentation. TSS group: 13 patients cured by transsphenoidal surgery.
BMI, body mass index; GV, growth velocity; MPC, midnight plasma cortisol; NS, means are not significantly different; UFC, urinary free cortisol.